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Summary
Primary antibody deficiencies require lifelong replacement therapy with
immunoglobulin (Ig)G to reduce the incidence and severity of infections.
Both subcutaneous and intravenous routes of administering IgG can be
effective and well tolerated. Treatment regimens can be individualized to
provide optimal medical and quality-of-life outcomes in infants, children,
adults and elderly people. Frequency, dose, route of administration, home or
infusion-centre administration, and the use of self- or health-professional-
administered infusion can be tailored to suit individual patient needs and
circumstances. Patient education is needed to understand the disease and the
importance of continuous therapy. Both the subcutaneous and intravenous
routes have advantages and disadvantages, which should be considered in
selecting each patient’s treatment regimen. The subcutaneous route is attrac-
tive to many patients because of a reduced incidence of systemic adverse
events, flexibility in scheduling and its comparative ease of administration, at
home or in a clinic. Self-infusion regimens, however, require independence
and self-reliance, good compliance on the part of the patient/parent and the
confidence of the physician and the nurse. Intravenous administration in a
clinic setting may be more appropriate in patients with reduced manual dex-
terity, reluctance to self-administer or a lack of self-reliance, and intravenous
administration at home for those with good venous access who prefer less
frequent treatments. Both therapy approaches have been demonstrated to
provide protection from infections and improve health-related quality of life.
Data supporting current options in IgG replacement are presented, and con-
siderations in choosing between the two routes of therapy are discussed.
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Introduction
Severe primary antibody deficiencies (PAD) require
lifelong immunoglobulin (Ig)G replacement therapy [1–3].
Throughout the 1980s and 1990s, intravenous IgG (IVIG)
administration was the most common method of replace-
ment in most countries [1,2], but subcutaneous IgG
(SCIG) has become established as a well-tolerated and
effective treatment, which is preferred by many patients
and their families [1,4–14]. Treatment regimens incorpo-
rating IVIG and SCIG products now allow physicians,
nurses and the parents/care providers to support
patients with widely different clinical backgrounds and
lifestyles.
Sufficient data have been accumulated to suggest that the
choice of IgG therapy for a patient with PAD is no longer
simply a binary decision between monthly IVIG and weekly
SCIG regimens. Variables which impact the choice of a
regimen in any given patient with PAD include total
monthly IgG dose, frequency and route of administration,
the device used for administration, volume and rate of infu-
sion, recommended IgG level at the end of an infusion cycle
(trough level), number of infusion sites, the product and/or
formulation used, site of care and administration of IgG,
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education and training of the patient and family, the
administration support system, and the occurrence and
management of adverse events (AEs), including the need for
pre- or post-medications (i.e. for prophylaxis or treatment
of post-IVIG headaches, ‘wear-off’ or end-of-dose fatigue
and other symptoms; Fig. 1). The availability of weekly,
bi-weekly or more frequent SCIG regimens with 16 or 20%
products, in addition to every 2-, 3- or 4-weekly intrave-
nous administration of 5 or 10% preparations or
hyaluronidase-facilitated SCIG (fSCIG) have significantly
expanded choices for patients.
Overall, higher IgG levels are associated with increased
resistance to infection. This has long been suggested for
IVIG, but has also been documented for SCIG [15,16].
However, studies suggest great variability in the IgG levels
required for different individuals to remain free from infec-
tion and in the dosing regimens needed to maintain the
necessary serum IgG levels [17–20], and thus the associa-
tion can only be drawn at the population level. Recent
advances to be considered in formulating the best treatment
approach for each patient are discussed.
Aim of IgG replacement therapy
The goal of long-term IgG replacement therapy is to reduce
the incidence and severity of infections and prevent long-
term deterioration in organ function [1,3,21]. Usually, this
requires normalization of serum IgG levels. Optimized
replacement IgG therapy may delay or abrogate the progres-
sion and development of complications in PAD, such as
bronchiectasis, autoimmune disorders or digestive tract dis-
orders, and retard development of progressive lung disease
[1,3,22]. The treatment also aims to improve the
self-perceived health-related quality of life (HRQoL) of
children, adults and elderly people with PAD [12,21,23–29].
The importance of accurate diagnosis to identify those
patients most likely to benefit from IgG replacement
therapy is of initial and paramount importance. Unsatisfac-
tory laboratory methods and the incorrect interpretation of
results can lead to institution of IgG replacement therapy
that is neither appropriate nor effective [30]. For example,
careful interpretation of antibody responses to the 23-valent
pneumococcal vaccine, with repeated determinations over
time, may be necessary to determine the need for long-term
IgG replacement therapy [30,31]. In some cases, an empiri-
cal trial of IgG may be indicated even when an underlying
PAD has not been diagnosed clearly. In other cases, it may
be appropriate to offer a patient a trial of discontinuation of
an established IgG treatment regimen to allow wash-out
and reassessment of the patient’s ability to maintain anti-
body levels and to mount protective vaccine responses.
The approach to the variables and goals of IgG therapy
may change at different stages of a patient’s life: living cir-
cumstances, degree of exposure to infectious diseases and
the onset of complications necessitating changes in therapy.
Routes of administration: IVIG and SCIG for
individualized therapy
The choice of administration route should consider a range
of clinical and patient parameters. Although IVIG replace-
ment therapy has been used for many years, there have been
more than 25 years of accumulated experience with SCIG
therapy in Europe, especially in the Nordic countries. SCIG
is now widely available in Europe, the United States and a
steadily growing number of other countries [24,32–37].
From a pharmacokinetic viewpoint, the principle differ-
ence between the subcutaneous and intravenous routes is
the slower rate at which IgG reaches the bloodstream fol-
lowing subcutaneous administration [38] and the frequency
of administration. The pharmacokinetics of IgG can be
described by a two-compartment model, with IgG in
equilibrium between the vascular and extravascular com-
partments [39,40]. IVIG is infused directly into the intra-
vascular compartment, immediately achieving high levels,
which fall very rapidly over the next several days as the IgG
is distributed into the extravascular compartment. The
overall extracellular volume is about twice that of the intra-
vascular compartment, so the IgG level re-equilibrates to
about half the peak level. Catabolism then causes the level
to drop more slowly over subsequent weeks. SCIG infusions
form an initial depot at the local site(s), after which IgG is
transported from the subcutaneous tissue into the lymph
and then into the bloodstream [41]. The lack of the rapid
attainment of a high peak IgG concentration with SCIG
(Fig. 2) is associated with a substantially reduced incidence
of systemic and severe AEs [38]. In addition, the near
steady-state serum IgG levels achieved with weekly or more
Route
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Fig. 1. Variables in immunoglobulin (Ig)G therapy. Akin to using
pure colour paints to create a complex image, there are numerous
variables in IgG therapy that can be applied to optimize the approach
to any given patient. Some variables, for which at least some data exist
supporting their adjustment in individual patients to improve
outcomes, are listed as paints on the painter’s palate.
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frequent SCIG administration confer comparable protec-
tion against infections [5,11,12,34,42–44]. In contrast,
recent pooled analyses showed that the incidence of infec-
tion increases as the IgG level falls towards the end of each
3- or 4-week IVIG dosing cycle [45]. It is not possible to
achieve the near steady-state IgG levels with weekly SCIG
[46–48] using IVIG.
The reduced incidence of systemic AEs and the compara-
tive ease of the subcutaneous infusion facilitate home-based
self- or family-administered SCIG regimens. However, this
treatment option requires a reliable, committed individual
and an experienced educator.
Most currently available IVIG formulations are associ-
ated with low rates of systemic AEs, which are generally tol-
erable and related mainly to the rate of infusion. These are
more likely to be encountered during the first or second
infusion of a given product (or if there is a concurrent
infection) [38,48,49]. However, in some patients, lower
trough IgG levels prior to the next dose of IVIG may cause
‘wear-off’ effects such as increased risk of infection, fatigue
and/or a sense of feeling ill in some patients [15,38]. For
these patients, either an increased IVIG dose, a shorter
interval between IVIG infusions or substitution for weekly
or more frequent SCIG infusions may be preferable [50]. In
specific clinical situations such as PAD-associated immune-
mediated cytopenia, IVIG may be more effective in quickly
raising the platelet or white blood cell count, owing to the
established immunomodulating effects. Conversely, patients
with gastrointestinal or renal protein loss might benefit
from the more gradually absorbed, smaller doses usually
used with SCIG.
In some countries, specific insurance or payor policies
regarding product, route, dose, and/or trough levels may
restrict the provider’s ability to optimize the treatment
regimen. However, a well-reasoned and referenced proposal
or a 3–6-month therapeutic trial to establish efficacy may
offer a way forward [3,51].
IgG therapy and health economics
Multiple factors, including product, method of delivery (i.e.
with or without a pump) and whether a dose adjustment
coefficient is used, may determine the relative cost of SCIG
compared with IVIG therapy. As SCIG is self-administered
by most patients, costs for facilities and health-care profes-
sionals should be reduced or eliminated. Swedish, German,
and Canadian studies have shown an economic advantage
in administering SCIG at home compared with hospital-
based IVIG therapy [7,52–55] and also a 50% reduction in
costs for the patients/families [7]. In Quebec, patients and
parents spent less time away from home or other activities
for SCIG therapy than for IVIG, and the total medical and
non-medical costs were significantly lower for SCIG than
IVIG (P < 0·001) [54]. In British Columbia, the cost to the
health-care system was reduced by CA$5736 per patient
over 3 years by using SCIG compared with previous IVIG
therapy [55]. An additional benefit for patients using SCIG
is the possibility to do something else during the sub-
cutaneous infusion. According to a recent survey of the
International Patient Organization for Primary Immunode-
ficiencies (IPOPI), the average time for performing a SCIG
infusion is less than 2 h, compared with approximately
2–6 h for an IVIG infusion [13,56]. Thus, the total time
spent for SCIG infusions in a month may be longer than the
time for IVIG infusion, but it is not perceived as ‘lost’ from
other activities [13], and the time required for transporta-
tion to the hospital or infusion centre is also regained by the
patient. There are hardly any studies comparing the costs of
home- and hospital-based IVIG therapy. A review of the
available literature concluded that the difference in therapy
costs between IVIG and SCIG is due mainly to home
therapy [27]. Home-based IVIG therapy may thus be
expected to be similarly less costly than the equivalent
hospital-based regimen and also not require the pumps
needed for SCIG; however, the corresponding costing
models are complex, with country- and service-specific
variation.
Dosing regimens
Dose
IgG trough levels are a useful aid to monitor the adequacy
of therapy and guiding care, but should be used in conjunc-
tion with a range of other clinical and laboratory findings to
individualize therapy. These include infection frequency,
antibiotic requirement, bronchiectasis, time lost from
school or work, underlying diagnosis [X-linked agamma-
globulinaemia (XLA) versus common variable immunodefi-
ciency (CVID)], the presence of IgA, inflammatory
markers, beta-2 microglobulin, imaging [57], potentially
the measurement of individual antibody levels to specific
pathogens [58], and, currently in a research setting, Fc
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Fig. 2. Serum immunoglobulin (Ig)G concentrations achieved with
intravenous Ig (IVIG) and subcutaneous Ig (SCIG). Serum IgG
concentrations for IVIG are from the pharmacokinetic study of
Privigen® in primary antibody deficiency (PAD) (n = 25) [99], those
for SCIG are from the pharmacokinetic study of Hizentra® (n = 18)
[100]. Mean values are shown.
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receptor polymorphism [3]. Even though a trough serum
IgG level of 5 g/l has been used by some as a minimal target
level, it is quite clear that different individuals require dif-
ferent IgG levels to remain free from infection and different
dosing regimens to achieve and maintain those levels [59].
According to recent studies and in the authors’ experience,
currently recommended average lower limits have increased
to 7–8 g/l [7,15,32,60,61], with each patient treated indi-
vidually. Lucas et al. have reported that patients with bron-
chiectasis require higher doses of IgG to achieve the same
serum levels as those without bronchiectasis and that
patients with XLA may require higher IgG levels than those
with CVID [19]. At the University Hospital of Wales
(Cardiff, UK), higher doses of IgG are given to patients with
end organ damage or XLA. These findings and many
authors’ clinical experience emphasize the need for indi-
vidualized IgG therapy.
Starting IgG doses currently tend to be 400–600 mg/kg
per 3 or 4 weeks for IVIG or 100–150 mg/kg per week for
SCIG [15,16,51,62,63]. Bonagura et al. suggested a biologi-
cal trough level for each patient to remain free from serious
acute infection, rather than establishing an arbitrary mean
based on the normal population [20]. Following regular
monitoring (which might include spirometry, lung diffus-
ing capacity and/or high-resolution computed tomography
scans), dose adjustments should be made based on clinical
outcomes and best practice for monitoring home therapy
[37]. However, the minimization of acute infections may
not necessarily prevent chronic infection (i.e. bronchiecta-
sis) and its complications.
Dose intervals
Regimens should allow the treatment to be integrated into
the patient’s specific life situation without causing undue
adverse effects or sacrificing clinical efficacy. Any infusion
frequency is feasible, from once every 4 weeks for IVIG to
several times per week for SCIG. Currently, for patients
receiving IVIG, administration every 2–4 weeks is used
depending on the clinical outcome [35,64]. In a survey con-
ducted by the US Immune Deficiency Foundation in 2007,
56% of patients received IVIG every 4 weeks, 27% every 3
weeks and 11% every 2 weeks; only a small proportion of
patients used intervals longer than 4 weeks [64]. Recent
treatment recommendations in the United States and
Europe are similar: in a 2010 survey, 87% of the American
Academy of Allergy, Asthma and Immunology (AAAAI)
members recommended a 4-weekly dose interval, whereas
the European Society for Immunodeficiency respondents
used 3- and 4-weekly intervals [35]. For SCIG treatment,
once-weekly has generally been preferred, but regimens
ranging from daily to bi-weekly have been used in children
and adults [5,13,42,44,62,64–67]. Diverse regimens can be
tailored to require minimal number of infusions or sites per
infusion depending on the patient’s tolerance, preference
and available time (Table 1). In one author’s experience,
patients with PAD experiencing joint pain or body aches
may prefer to use daily or every-other-day SCIG infusions.
The usual practice of switching from IVIG to SCIG
therapy in Europe has been to use the equivalent monthly
IgG dose split into four equal weekly doses (1:1 dosing)
[68,69]. Despite the recommendation of the US Food and
Drug Administration to use a dose adjustment coefficient to
achieve similar total exposure to IgG (non-inferior area
under the curve of serum IgG concentration plotted versus
time) [16], studies of clinical practice in the United States
suggest that physicians are not necessarily heeding that rec-
ommendation, as there was no difference in the total
monthly doses used by the intravenous and subcutaneous
routes [70,71]. The impact of equivalent IVIG and SCIG
dosing on frequency of infection and long-term outcomes
remains to be seen, but available data suggest that even
within the ‘normal’ range of serum IgG levels, higher levels
provide better protection [16].
Infusion rate
Many of the systemic, infusion-related AEs with IVIG, such
as headache, chills and/or malaise, can be alleviated by
adjusting the infusion rate according to the individual
patient’s tolerance and/or by reducing it when symptoms
occur [72]. More than 60% of the responders of the First
National Immune Deficiency Foundation Survey in 2002
and of a Swedish survey reported experiencing infusion
rate-related AEs with IVIG [56,73]. Among current intrave-
nous products, the newer 10% liquid IVIG formulations
can be administered at infusion rates of up to approxi-
mately 5 ml/kg/h [74,75] or even 7·2 ml/kg/h [72].
For SCIG 16% products, the maximum recommended
infusion rates are 10–20 ml/h. The maximum recom-
mended rate for SCIG 20% is 15 ml/h/site for the first
infusion and 25 ml/h/site for subsequent infusions, but
these have largely been chosen to avoid side effects during
registration trials that did not aim to determine the
maximum rate or volume per site tolerated. ‘Express’ rates
of up to 70 ml/h have been used successfully in some
centres [8,47,48]. It has been shown that an infusion rate of
35 ml/h does not create more local AEs than 20 ml/h [8].
However, AEs (e.g. local pain or pronounced swelling
and/or persisting local reactions) associated with very high
infusion rates or volumes should be avoided when adjusting
therapy for individuals.
Infusion volume
IVIG infusions are seldom limited by volume concerns,
although volume may be an issue in some patients with
cardiac or renal disease. In contrast, with SCIG, the volume
infused per site and the number of sites per infusion should
be limited to what can be tolerated comfortably by the
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patient and may be influenced by the product, dose and
duration of each infusion. While IVIG is generally available
as a 5 or 10% formulation, SCIG is available in 10, 16, 16·5,
or 20% solutions. The availability of 16–20% SCIG solu-
tions allows larger doses to be administered in smaller
volumes. When using SCIG, larger volumes can be accom-
modated using several simultaneous sites per infusion
and/or more frequent infusions. Total doses of as much as
50 ml infused simultaneously into two to three sites can be
tolerated easily by most adults, even elderly patients [76]. In
the authors’ experience, up to 80 ml into a single site can be
tolerated. It is important to choose a comfortable infusion
rate and volume per infusion site in each patient when indi-
vidualizing the SCIG therapy. However, increasing both
variables at the same time may complicate resolving poten-
tial local tissue AEs.
Number of infusion sites
The number of subcutaneous infusion sites used during
each infusion differ widely. Up to four sites are used by
most patients [7,9,42,76,77], either sequentially or simulta-
neously [11,69], but as many as six to eight sites have been
used for single infusions. The flexibility of using different
number of sites, volumes per site, infusion duration, and
interval allow infusion regimens to integrate with the life-
style of individual patients (Table 1). Portable infusion
pumps and bifurcated or more highly branched tubing sets
can be used to facilitate any desired regimen, and can limit
the total time required for SCIG treatment.
SCIG treatment of patients previously untreated
with IgG
If the subcutaneous route is chosen, initiation of therapy in
previously untreated patients sometimes includes a
‘loading’ phase. Initial loading with 100 mg/kg daily for
5 consecutive days [12] increases serum IgG levels to target
levels of more than 5 g/l within 1 week (Fig. 3) and also
provides a good opportunity for effective training for subse-
quent self-infusion at home [47]. Weekly SCIG raises the
IgG more gradually, reaching levels >5 g/l after 3–4 weeks
[65], with steady-state levels reached after 6 months. In the
US registration trials and in patients in whom serum IgG
levels must be raised rapidly, IVIG is given first, followed by
a switch to SCIG therapy for maintenance [48].
Experience in specific patient subpopulations
Pediatric populations
Rapid SCIG infusion therapy [9] was adopted for use in
children in the 1990s [78]. Optimal treatment of children
and infants aged less than 2 years is particularly important
in order to prevent the development of chronic lung infec-
tion. Although trough IgG levels are generally targeted in
the same way and in the same range as for older children
and adults, early rigorous treatment may favor better clini-
cal outcomes and minimize lung complications [62,79].
Overall, all studies in pediatric patients indicate that man-
agement of primary immunodeficiencies with IVIG therapy
begun early in life is well tolerated, effective, and improves
patients’ HRQoL [62,79,80].
The ease of administration and good tolerability of SCIG
in children allows maintenance of adequate IgG levels and
successful management of infections, resulting in fewer days
in hospital and days missed from school or day care
[12,43,69]. Similar results were observed in studies evaluat-
ing the HRQoL of pediatric patients on SCIG therapy
[5,21,81]. Home therapy with weekly SCIG resulted in
greater independence, reduced the periods of absence from
school and social activity, enhanced freedom to travel,
decreased disruption of daily activities, improved therapy
convenience and comfort, and provided better treatment
flexibility as opposed to hospital-based IVIG treatment
[5,21]. Psychological preparation and play therapy during
the nurse-led training for IgG replacement in children is
important to assist the child and family. For occasional
pediatric patients with family situations that preclude home
therapy, SCIG administration in a clinic or hospital day unit
may be the preferred option.
Elderly patients
As a patient group, elderly people are more likely to have
co-morbid conditions, such as impaired cardiovascular
and/or kidney function, and to be receiving concomitant
medications that might be considered to potentially
increase the risk and/or severity of AEs. Age-related changes
in the circulatory system, subcutaneous and connective
tissues might also be expected to affect the dynamics and/or
tolerability of SCIG [76]. Further, reduced dexterity, lack of
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Fig. 3. Serum immunoglobulin (Ig)G levels in previously untreated
patients. Loading 1 included administration of 100 mg/kg daily for 5
days (n = 18); the maintenance regimen was 100 mg/kg once weekly
thereafter [12]. With loading 2, patients (n = 13) received 100 mg/kg
twice a week for 2 weeks; the maintenance regimen was 100 mg/kg
once weekly [101]. Mean values are shown.
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self-confidence or an infusion partner and resistance to
change may make self-infusion at home more challenging
in elderly patients. For these reasons, some elderly patients
prefer IVIG infusions administered by trained professionals
at a clinic or infusion centre.
However, travel to the office or infusion centre might be
challenging for some elderly patients. Studies have shown
that home-based SCIG appears to be well tolerated, effective
and practical in patients aged more than 65 years [76].
Moreover, none of the patients, including patients with dia-
betes and patients who received anti-coagulant or anti-
platelet therapy, experienced problems with local reactions
such as bruising, bleeding or skin breakdown [76]. The lack
of local site complications in patients on concomitant anti-
coagulant or anti-platelet therapy has also been confirmed
in a wider age range (3–89 years, median 70 years) of
patients with PAD receiving maintenance SCIG therapy
[82]. SCIG treatment every 2 weeks (bi-weekly) was also
tolerated well by elderly patients [42].
IgG use during pregnancy
In a study of pregnant women with PAD, weekly SCIG infu-
sions were well tolerated and effective in nine women
during 11 pregnancies [83]. During pregnancy, women
switched infusion site from the abdominal wall to the thigh
for convenience reasons. IgG dose is usually increased in the
last trimester to compensate for placental IgG transfer, but
can also be adjusted based on the increased weight during
the pregnancy. This gradual increase of the dose may be
more convenient for the woman [83]. After more than 400
infusions, no systemic AEs or marked local tissue reactions
were observed. Gestation was normal in all cases and all
babies were born in a healthy condition with normal serum
IgG levels and IgG subclasses, with no requirement for
additional IgG therapy following birth.
Patients with obesity
SCIG (16 or 20%) administered by infusion pump or push
administration was effective and well tolerated in obese
patients, providing a practical alternative to IVIG without
the need for special dosing adjustments [77]. Dose to serum
IgG level ratios were similar in obese and non-obese
patients, consistent with equivalent bioavailability regard-
less of body mass index (BMI): there was no evidence sup-
porting a need for SCIG dose adjustments in obese patients
with PAD [77]. Nevertheless, treatment guidelines in Aus-
tralia, Canada, and the United Kingdom have suggested
dose adjustments in obese patients based on lean body
weight – mainly in the context of immunomodulatory IgG
doses – as a potential cost-saving mechanism, although
there is little published evidence to support this approach
[84]. Rates of AEs, mostly of injection-site reactions, were
slightly lower among obese (15·8% of visits) compared with
non-obese (17·6% of visits) patients [7,77].
Administration practicalities
Devices for administration: pump, syringe
Individual patient preferences, cost and local policies may
all be considered in deciding whether to administer SCIG
using small portable infusion pumps (‘pump’) or simply
pushing the IgG from a syringe. Volumes of less than 20 ml
can be pushed directly, with only one or two sites per infu-
sion. This often necessitates more frequent dosing, but each
infusion usually takes much less time. A retrospective analy-
sis in 104 patients found that for push administration using
a syringe, volumes of 3–20 ml were administered during
5–20 min at an average frequency of two to three times per
week [66]. More than 80% of patients using the rapid push
infusion used only one infusion site per session, with 20 ml
as the most common total volume infused (67·3% of
patients). An additional 18·6% of patients infused 10–14 ml
per infusion. The frequent push technique is considered
much more convenient by some patients [66]. A more
recent analysis of administration techniques in a larger
cohort (173 patients) confirmed these results: the mean
(±standard deviation) infusion volume was 15·0 ml
(±7·3 ml) and the time needed for each infusion was sub-
stantially lower than that for pump administration [67].
Similar results were obtained in pediatric patients [85]. As
the push technique requires no pump or tubing, the cost for
equipment and its maintenance is reduced [47].
Regardless of whether using pump or ‘push’, the choice of
needle length and gauge can have a marked effect on toler-
ability [86]. Sufficiently long needles (9–15 mm in adults)
are essential for delivering the drug into the subcutaneous
tissue rather than the dermis, but needles which are too
long may deliver the IgG into muscle [86]. Erring on either
side of the subcutaneous tissue has the potential for causing
pain and discomfort. A 3⁄4″ × 23–25-gauge butterfly needle
is usually used for syringe administration in adults [9,47].
For infants, a 24–27-gauge, 4–6-mm needle is appropriate
[14]. Equipment for measuring the thickness of the subcu-
taneous tissue is now available, making it easier to choose
the correct needle length. The needle tip can also contribute
to better tolerability, with the tricuspid type being usually
better tolerated than the lancet type [86]. Not surprisingly,
patients with a lower BMI experience infusion-site reactions
more frequently [7]. Local itching experienced after infu-
sions by some patients may be due to mechanical and/or
chemical local mechanisms affecting superficial, dermal
sensory nerve fibres [7].
Crono PCA-50 or Super-PID infusion pumps (Cane
S.R.L., Turin, Italy) are used predominantly in Europe,
while the FREEDOM60 syringe infusion system (Repro-
Med Systems, Inc., Chester, NY, USA) is preferred in the
S. Jolles et al.
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United States [47]. The tubing size for FREEDOM60 is used
to adjust the infusion rate, and thus has to be chosen
according to the rate tolerated by the patient [86].
In a Swedish survey comprising 841 adults with PAD
receiving IgG therapy, 20% of those receiving IVIG at the
hospital reported that inserting the intravenous needle was
often a problem. The needle was often placed in the
antecubital vein (44%), followed by the radial side of the
wrist (20%), the back of the hand (18%) or in an already-
established port-à-cath (17%). However, the use of long-
term indwelling catheters should generally be avoided in
immunodeficient patients due to the risk of infection. Of
those on IVIG self-infusions at home, a clear majority
(71%) placed the needle on the back of the hand. Most of
the adults on SCIG therapy used sites on the abdomen
(74% of those at home; 63% of those at the hospital). A
23–25-gauge butterfly needle was used by a majority of the
patients on SCIG (87% home; 70% hospital) [73]. In the
United States, butterfly needles are infrequently used for
SCIG, as most patients receive commercially available SCIG
needles such as Clear-Vue® (Best, the Netherlands).
Site of care
IgG replacement therapy may be administered in a hospital,
clinic or infusion center setting, at the doctor’s office, at
home or, in some cases, even as self-infusions at work. The
AAAAI site of care guidelines recommend highest level of
physician supervision in a hospital or practice, so that any
AEs can be handled appropriately [87]. In stable patients
who are tolerating therapy well, the site of care can be
changed to a lower level of supervision and a less controlled
environment. Home-based IVIG self-administration is pre-
ferred by some patients after appropriate education and
evaluated to be safe [88]. At the University Hospital of
Wales (Cardiff, UK) and in Sweden, approximately 80% of
the newly diagnosed adult patients commence home SCIG
therapy after appropriate education and assessment. A
recent survey by IPOPI showed that among 300 patients in
10 countries, 14% of patients on IVIG and 94% for those
on SCIG received therapy at home [13].
Administration personnel and training programs
Patients usually prefer self-administration at home, as it
increases flexibility, HRQoL and self-perceived health
[9,23,24,26,28,29,69,73,81,89]. Self-administration is more
practical with SCIG than IVIG, but IVIG self-infusions are
possible at home [13,73,88] or administered by a nurse for
patients anxious about needles or self-infusions. Self-
administration requires patients or caregivers to undergo
education and training until they feel comfortable to
perform infusions on their own and demonstrate their
competence to the trainer. In most cases this is accom-
plished within three to six infusions, but training
programs may differ by country [47]. In many cases,
instruction in SCIG involves newly diagnosed patients or
those taking increased responsibility for their own care.
Therefore, it is important that the education and training
program includes education about PAD, aims and impor-
tance of IgG therapy, infections, systemic adverse reactions
including management of any severe reactions, self-care and
infection prevention, behavior changes (e.g. the IgG therapy
itself being a change in life, smoking cessation, maintaining
play time and activities), and self-infusion technique,
including safety measures before starting the infusion [37].
Some providers have concerns about higher rates of sys-
temic AEs accompanying self-administration of IVIG at
home as opposed to SCIG. Therefore, a reliable system of
reporting AEs associated with home-based infusions has to
be developed. Support for pediatric patients may include
the use of ‘play therapy’ to improve adherence to treatment
regimens.
Use of hyaluronidase to facilitate SCIG administration
The use of hyaluronidase to facilitate dispersion of larger
volumes of liquid into the subcutaneous space has been
suggested to help absorption of a number of drugs, includ-
ing IgG [90]. In an open-label multi-center Phase III study
of administration of hyaluronidase followed by subcutane-
ous immunoglobulin (IGHy), a mean volume of 292·2 ml
of 10% Ig was administered using one site every 3 or 4
weeks and serum IgG trough levels were similar with
IGHy and IVIG [91]. The area under the serum IgG
concentration–time curve suggested a bioavailability of
86% for IGHy compared with approximately 67% for SCIG
without hyaluronidase [71]. The overall rate of infection
was 2·97 days per patient-year for IGHy compared with 4·51
for previous IVIG. IGHy may be practical for patients who
prefer infrequent (e.g. 2–4-weekly) dosing, although ‘wear-
off’ effects towards the end of the longer cycle may be an
issue, as with IVIG. Recombinant human hyaluronidase has
been well tolerated in occasional use; however, only rela-
tively small numbers of PID patients, mostly in studies,
have been treated repeatedly with limited long-term follow-
up. IGHy is approved in Europe and the United States for
use in adults; in Europe, it is not approved in women who
are pregnant or planning to become pregnant [92,93]. The
extent to which IGHy will be used in future will depend on
longer-term experience and follow-up and cost–benefit
analysis.
Special situations
SCIG administration has been reported to be more compat-
ible with an active lifestyle, including sports and schooling,
and more convenient during business trips or holiday
[13,21,24,26–28,68,69]. Ninety per cent of patients receiv-
ing IVIG report having skipped a dose compared with 18%
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of those receiving SCIG therapy, and 45% of patients with
SCIG self-administered doses with delay by 3 or more days
at least once in the last 6 months [8,13]. The choice between
SCIG and IVIG for patients who travel frequently depends
upon the time spent away from home and whether travel-
ling with equipment is needed.
For surgery, the recommendation is to ensure that a dose
is given close to and preceding the surgery date.
Patients with anti-IgA antibodies require careful assess-
ment, as high-titre anti-IgA antibodies have been associated
with severe anaphylactic reactions, and in some countries
they are not treated with IVIG. Patients with high titres of
anti-IgA antibodies have been treated successfully with
SCIG in Sweden [9,94–97].
Management of AEs
Available products differ substantially and, as a result, some
patients tolerate different products differently. In patients
with adverse reactions, a switch from one product to
another may be needed [98]. Once a patient is stabilized on
a specific product, that same product should be continued
to ensure good tolerability and stable therapy [3]. Products
should not be changed without consent and oversight of the
physician.
Different types of AEs are observed with IVIG and SCIG
therapy: the former is associated with a higher rate of sys-
temic AEs such as headache, nausea, and fatigue, while the
latter is accompanied mainly by local infusion-site reac-
tions. Although initial local tissue reactions are to be
expected with SCIG, they are usually considered only ‘mild’
or ‘moderate’ and their frequency decreases with prolonged
therapy (Fig. 4) [47,69].
The infusion technique and materials used are important
for good tolerability of SCIG infusions; the change from a
6- to a 9-mm needle reduced local AEs in some patients
[86]. It is also important to individualize the choice of
infusion sites: some adult patients will prefer to use the
thighs, others the abdomen and others the combination of
both or the backs of the arms. Some patients prefer to alter-
nate between several sites, while others find that the use of
new sites results in an increased rate of local reactions. In
either case, long-term changes at infusion sites such as
tissue scarring or atrophy have not been reported. There are
limited long-term data concerning the regular use of
hyaluronidase in the same site.
Alleviation of AEs
Most systemic AEs typical of IVIG treatment (headache,
nausea and fatigue) occur during the infusion or within 2
days after it, when the serum IgG level is at its peak. Reduc-
tion of the infusion rate is often sufficient to alleviate AEs.
Premedication with anti-pyretics, anti-histamines and/or
short-term corticosteroids can be used with IVIG to ame-
liorate systemic AEs [1]. In some patients, the switch to
SCIG and a more steady-state serum IgG level has alleviated
recurrent problems such as severe post-IVIG headaches,
which are presumably related to the pharmacokinetics of
the intravenous route.
Selection of the appropriate therapy regimen
Confirming the diagnosis necessitating IgG therapy is the
first step in the proposed algorithm for selecting the right
therapy for each patient (Fig. 5). Determining whether
IVIG or SCIG will be used requires information about
personal preferences, venous access, dose required, toler-
ability to previous IgG treatment, lifestyle, and in-depth
discussion with the patient/parents. Although care must be
taken to agree to an initial treatment plan at the outset,
subsequent support, especially for home therapy, is essen-
tial. As the patient becomes familiar with his/her disease
and its treatment, the regimen should be reviewed and
adjusted as needed, and changes in living circumstances
and/or exposure to infectious diseases should be consid-
ered. With current products, routes of administration, and
pumps/devices, there should always be the flexibility
to modify the regimen to fit changing requirements or
preferences.
Conclusions
It is now possible to adjust individually the IgG adminis-
tration route, infusion technique, frequency of infusion,
number of infusion sites, and volumes to suit patients of
any age or circumstance (pregnancy, infants and elderly
people) with IVIG or SCIG regimens. Measures that
increase the flexibility and convenience of therapy are
important, and choices may be different for pediatric and
elderly patients. The range of options now includes IVIG
with 5 and 10% products, SCIG products at 10, 16, 16·5,
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and 20% concentrations with weekly, bi-weekly, and rapid
push regimens as well as fSCIG. These allow the tailoring
of an optimal IgG regimen to enhance compliance,
strengthen patient and provider confidence, improve
HRQoL, and achieve the best possible clinical and patient
outcomes.
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